ABPRO Holdings Inc
NASDAQ:ABP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ABPRO Holdings Inc
Selling, General & Administrative
ABPRO Holdings Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ABPRO Holdings Inc
NASDAQ:ABP
|
Selling, General & Administrative
-$7.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alumis Inc
NASDAQ:ALMS
|
Selling, General & Administrative
-$91.9m
|
CAGR 3-Years
-94%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Grail Inc
NASDAQ:GRAL
|
Selling, General & Administrative
-$275.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Oruka Therapeutics Inc
NASDAQ:ORKA
|
Selling, General & Administrative
-$21.4m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-17%
|
|
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
Selling, General & Administrative
-$30.3m
|
CAGR 3-Years
-189%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Metsera Inc
NASDAQ:MTSR
|
Selling, General & Administrative
-$26.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ABPRO Holdings Inc
Glance View
ABPRO Holdings Inc is a US-based company operating in industry. The company is headquartered in New York City, New York. The company went IPO on 2022-01-14. Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The firm is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.
See Also
What is ABPRO Holdings Inc's Selling, General & Administrative?
Selling, General & Administrative
-7.1m
USD
Based on the financial report for Dec 31, 2024, ABPRO Holdings Inc's Selling, General & Administrative amounts to -7.1m USD.
What is ABPRO Holdings Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 1Y
6%
Over the last year, the Selling, General & Administrative growth was 6%.
